Drug intelligence / Profile preview

rVSV(M51)-M3

Development stage
Preclinical
Modality
Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration
Intra-arterial (hepatic Artery Infusion; Preclinical)
01

Overview

rVSV(M51)-M3 is a genetically engineered, replication-competent recombinant vesicular stomatitis virus (VSV) with a deletion/mutation at position 51 (MΔ51) in the matrix (M) protein and engineered to express M3—a secreted chemokine-binding protein derived from murine gammaherpesvirus-68. Its primary mechanism is oncolytic: it infects and lyses tumor cells while the M3 protein suppresses host inflammatory chemokine responses within the tumor microenvironment. This action results in enhanced viral replication within tumors, increased tumor necrosis, and reduced recruitment of immune cells (such as neutrophils and natural killer cells) that would otherwise limit viral spread. Preclinical studies show it is safe and effective in animal models of multifocal hepatocellular carcinoma (HCC), achieving long-term tumor-free survival in a significant number of treated animals, with no observed systemic or organ toxicity[2][4].

Other names
rVSV(MΔ51)-M3rVSV(M Delta 51)-M3

Beyond the preview

Go deeper on rVSV(M51)-M3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rVSV(M51)-M3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call